Construction of Evaluation Index System for the Policy Effect of Centralized Drug Procurement

Abstract

Objective To construct an index system for evaluating the policy effect of centralized drug procurement, and to provide reference for comprehensively and systematically evaluating the policy of centralized drug procurement. Methods Through combing the policies and literature research, the focus and expected goal of China’s centralized drug procurement policy were clarified. On the basis of policy concerns, combined with some theories and the implementation of drug centralized procurement policy, a primary evaluation index system was constructed. The index system was determined by expert consultation, and the weight of each index was calculated by analytic hierarchy process. Results and Conclusion The questionnaire recovery rates of the two rounds of expert consultation were 88.23% and 100%, the coefficients of authority of experts were 0.86 and 0.80, and the expert coordination coefficients were 0.338 and 0.294, respectively. Finally, the evaluation index system for the policy of centralized drug procurement was established, which included 4 first-level indicators, 10 second-level indicators and 23 third-level indicators. The evaluation index system constructed in this paper can not only make up for the deficiency of systematic evaluation of the policy effect of the current centralized drug procurement, but also provide reference for further improving this policy.

Keywords

centralized drug procurement / stakeholder / policy evaluation

References

[1] Carone G, Schwierz C, Xavier A. Cost-Containment Policies in Public Pharmaceutical Spending in the EU[M]. Belgium: European Union, 2012: 33-37.

[2] Mills M, Kanavos P. Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe[J]. Health Policy, 2020, 124 (3): 239-251.

[3] Southen African Development Community. Strategy for Pooled Procurement of Essential Medicines and Health Commodities. 2013-2017 [EB/OL]. (2021-08-17)[2023- 04-19]. https://www.sadc.int/sites/default/files/2021-08/SADC_Strategy_for_Pooled_Procurement_of_Essential_Medicines_and_Health.pdf.

[4] General Office of the State Council. Notice on Printing and Distributing the Pilot Program of Centralized Drug Purchase and Use Organized by the State[EB/OL]. (2019-01-01)[2023-04-19]. http://www.gov.cn/gongbao/content/2019/content_5361793.htm.

[5] National Health Insurance Bureau and other nine departments. Opinions on the Implementation of the National Organization of Centralized Drug Procurement and Use Pilot to Expand the Regional Scope[EB/OL]. (2019-09-25)[2023-04-19]. http://www.gov.cn/zhengce/zhengceku/2019-09/30/content_5456439.htm.

[6] General Office of the State Council. Opinions on Promoting Normalization and Institutionalization of Centralized Drug Purchase[EB/OL]. (2021-01-22) [2023-04-19]. http://www.gov.cn/gongbao/content/2021/content_5585228.htm.

[7] Ahmadi A, Pishvaee MS, Heydari M. How group purchasing organizations influence healthcare-product supply chains? An analytical approach[J]. Journal of the Operational Research Society, 2018, 70: 280-293.

[8] Bruhn WE, Fracica EA, Makary MA. Group purchasing organizations, health care costs, and drug shortages[J]. The Journal of the American Medical Association, 2018, 320: 1859-1860.

[9] Shu Qian, Yao Zhengrong, Wang Yanhui, et al. Stakeholder analysis of drug consumption policy[J]. Health Economic Research, 2019, 36 (8): 8-9+12.

[10] China government network. The average price reduction of the first six batches of drugs was 53%[EB/OL]. (2022-02- 12)[2023-04-19]. http://www.gov.cn/zhengce/2022-02/12/content_5673237.htm.

[11] Wang Junman, Wen Jin. Developing the indicator system for evaluating health in all policies in earthquakestricken areas with Delphi method[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21 (7): 754-759.

[12] Yang Xinyue, Li Yibing, Hai Sang. Research on competitiveness and market efficiency of China’s pharmaceutical industry - analysis of the impact of quantity procurement on drug prices[J]. Price: Theory & Practice, 2019 (1): 51-55.

[13] Ma Fangfang, Wu Jing. Methodological selection strategy analysis on medicine price index[J]. Chinese Journal of Health Policy, 2015, 8 (7): 61-67.

[14] Chinese Government Network. End of 60 Years of “Medication Supplement Medicine” [EB/OL]. (2017-10-15)[2023-04-19]. https://www.gov.cn/xinwen/2017-10/15/content_5231775.htm.

[15] Wu Tian. Research on centralized purchasing price and drug cost control of medicines[J]. Health Economics Research, 2018, 380 (12): 32-34.

[16] Cheng Wenwen, Yu Fei, Zhang Siyu, et al. Research on the construction of risk assessment index system of drug supply chain in public hospitals based on stakeholder theory[J]. Chinese Pharmaceutical Affairs, 2022, 36 (5): 593-602.

[17] Sun Zhenqiu. Medical Comprehensive Evaluation Method and Its Application[M]. Beijing: Chemical industry press, 2006.